Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Low Cost Biosensor to Be Based on Printing Technologies

By LabMedica International staff writers
Posted on 14 Sep 2011
Scientists intend to use the latest printing technologies to develop a low cost biosensor capable of diagnosing a range of health conditions.

Living antibodies will be placed into a suitable ink and then printed onto a compatible substrate or material to form a disposable sensor, capable of being mass-produced at low cost. More...
The printed array of antibodies speeds up the testing process while reducing the expertise and complexity of equipment needed--introducing the possibility of hand held electronic scanners and far quicker diagnosis.

Antibody based assays are routinely used to detect specific medical conditions but use of these tests is limited because they need to be carried out in laboratories by highly skilled technicians, which is costly and time consuming.

The team developing the new technique is led by Prof. Tim Claypole, head of Swansea University's Welsh Center of Printing and Coating (Wales, United Kingdom). Prof. Claypole said the project is at the forefront of international research and represents a major advance in the printing of biomedical sensors.

“The availability of low cost, disposable sensor technology is a core requirement for the early diagnosis of disease. The use of antibodies as sensors targeted to detect specific human conditions is regarded as one of the next major advances in health care.

“Volume printing is also the most practical method to achieve low cost disposable sensor technology. This will take innovation from the bench to the bedside and develop the tools and technologies to move the process of diagnosis forward and bring it into the surgery and home.”

In addition to allowing some aspects of patient care to be moved from the hospital or laboratory to the GP surgery, the new biosensor technology could also be useful in emergency situations and in remote areas.

The project is supported by the Welsh Government's Academic Expertise for Business (A4B), an EU funded initiative to stimulate and encourage collaboration between educational institutions and industry.

The initial focus will be developing a proof of concept device that will open opportunities to develop antibody sensors to diagnose a broad range of health conditions.

Related Links:

Swansea University's Welsh Center of Printing and Coating
Welsh Government's Academic Expertise for Business




Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.